AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) and Iambic announced a multi-year collaboration to apply Iambic's AI-driven molecular superintelligence platform to discover and develop small molecule therapies in immunology, neuroscience and oncology.
The partnership will use Iambic technologies including Enchant v3, a next-generation multimodal transformer model trained on over 6,000 molecular properties, and NeuralPLexer to optimize many drug candidate properties simultaneously, aiming to improve prediction accuracy and shorten discovery timelines. AbbVie plans to pair these tools with its therapeutic area expertise to design better molecules more efficiently and raise the probability of success in R&D. Under the agreement, Iambic receives an upfront payment and is eligible for success-based milestones and tiered royalties on net sales of products arising from the collaboration.
AbbVie (ABBV) presented new real-world and additional clinical data on VRAYLAR (cariprazine) at Psych Congress 2026 in New Orleans on September 18, 2026.
In the prospective CReW BP-I study of adults with bipolar I depression, mean MADRS scores decreased from 32.2 at baseline to 19.9 at week 12 and FAST functioning scores fell from 43.4 to 30.7, with exploratory quality-of-life and symptom measures also improving (p<0.0001 for all); nausea and dizziness were the most common adverse events (5.1% each. In the ongoing ProACt MDD study of adjunctive VRAYLAR, interim data from 76 patients showed PHQ-9 scores falling from 15.7 to 7.1 by week 6, with 76.3% reaching minimal/mild depression severity and notable improvements in functioning, motivation, energy and anhedonia.
AbbVie also reported indirect comparative data versus lumateperone in MDD, long-term pediatric safety results indicating VRAYLAR was generally well tolerated, and survey findings that most MDD patients prefer augmenting rather than switching antidepressants.
AbbVie (ABBV) will present full Phase 3 CERVINO results for investigational BCMA x CD3 T-cell engager etentamig at the 2026 International Myeloma Society (IMS) meeting in Glasgow, where the drug met dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
The company will also share multiple presentations spanning real-world outcomes, treatment patterns, infection-related healthcare utilization and costs, and combination strategies. Additional data will cover investigational assets ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 inhibitor, including monotherapy and combination studies across different myeloma settings. All three agents remain investigational and are not approved by health authorities.
Allergan Aesthetics (ABBV) reported results from two small, single-center clinical studies on targeted skincare regimens, alone and combined with DiamondGlow® dermabrasion, in individuals taking medical weight loss medications, including GLP-1 receptor agonists. The data are being presented at the 2026 Science of Skin Summit in Austin, Texas.
The 12-week skincare-only study had nine participants who completed the study, and the six-week DiamondGlow® plus skincare study had 11 participants with at least one post-treatment assessment. Investigators observed statistically significant visible improvements in selected skin quality measures such as dryness, tone evenness, crepiness, tactile roughness, lines and wrinkles, and texture as early as week two in the skincare study, and immediately after DiamondGlow® treatment in the combination study. Participants across both studies reported high satisfaction, and some reported facial skin appearing about 10 years younger after four weeks of serum use or about 7.5 years younger after three DiamondGlow® treatments plus six weeks of skincare.
AbbVie (ABBV) has been named Official Pharmaceutical Sponsor of the PGA TOUR and the 2026 Presidents Cup and is launching the Birdies for Brain Health campaign with the TOUR.
The multi-year initiative will debut at the 2026 Presidents Cup at Medinah Country Club, with an initial donation shared among six advocacy groups focused on migraine, mental health conditions and Parkinson's disease. In 2027, donations tied to every birdie will extend to PGA TOUR Signature Events and the FedExCup Playoffs. AbbVie will also collaborate with golfer Gary Woodland, a 2019 U.S. Open champion and 2026 Presidents Cup U.S. captain's assistant, to promote awareness through storytelling and engagement.
Allergan Aesthetics (ABBV) will highlight skin longevity, aging biology and exosome science at the 2026 Science of Skin Summit in Austin, Texas, from September 17–20, 2026.
The company’s R&D leaders will discuss the hallmarks of aging, regenerative aesthetics and evidence-based innovation in skincare. A featured SkinMedica® R&D panel will introduce the FACTS Principles, a science-based framework intended to guide consistent evaluation of exosome-based skincare technologies across formulation and stability, analysis, clinical studies, type of cellular origin and safety. Allergan Aesthetics and SkinMedica® will also host a booth experience and multiple scientific sessions focused on longevity science and exosome research.
AbbVie (ABBV) declared a quarterly cash dividend of $1.73 per share, payable on November 16, 2026, to shareholders of record as of October 15, 2026.
The company states that since its 2013 inception it has increased its dividend by more than 330% and is included in the S&P Dividend Aristocrats Index, which tracks companies that have raised dividends annually for at least 25 consecutive years.
AbbVie (ABBV) reported positive Phase 3 LUNA trial topline results for atogepant in menstrual migraine on September 10, 2026.
The randomized, double-blind, placebo-controlled study in 468 adult women evaluated atogepant taken for seven consecutive days starting three days before menses, over three menstrual cycles. Atogepant met the primary endpoint, reducing migraine days during the perimenstrual period by an average of 1.20 days versus 0.40 days with placebo, for 0.80 fewer migraine days versus placebo (p<0.0001). All eight ranked secondary endpoints, covering headache burden, acute medication use, functional disability, cognitive function and responder outcomes, also showed statistically significant improvements versus placebo (p<0.0001).
Safety findings were consistent with the known safety profile of atogepant, with no new safety signals observed. AbbVie plans to submit LUNA data to health authorities worldwide and present the results at future medical congresses.
AbbVie (ABBV) reported positive topline Phase 3 CERVINO results showing investigational BCMA x CD3 bispecific etentamig improved objective response rate and progression-free survival versus standard available therapies in triple-class exposed relapsed/refractory multiple myeloma.
Among 393 patients with a median of three prior treatment lines and 11.4 months median follow-up, etentamig achieved a significantly higher ORR of 74.0% versus 45.7% with investigator’s choice therapies and improved PFS with a hazard ratio of 0.40, with benefit seen across all pre-specified subgroups. Twelve‑month overall survival was 87.9% with etentamig versus 72.0% with standard therapies (HR 0.48), although the prespecified OS efficacy boundary was not crossed. Safety with a single step-up dose and monthly dosing showed low, mostly grade 1 cytokine release syndrome (28.3% CRS, no grade ≥3) and low treatment-emergent adverse event discontinuations (3.6% vs 9.6%). The Independent Data Monitoring Committee recommended unblinding based on the significant benefit, and AbbVie plans discussions with global regulators.
AbbVie (ABBV) completed its acquisition of Apogee Therapeutics (APGE), paying $135.11 in cash per share, implying equity value of approximately $10.9 billion as of September 3, 2026.
The acquisition adds Apogee's immunology pipeline, led by zumilokibart, a late-stage, half-life extended IL-13 monoclonal antibody in development for atopic dermatitis and other inflammatory diseases. In a Phase 2 trial in atopic dermatitis, roughly two-thirds of patients on zumilokibart achieved significant skin clearance at 16 weeks, with improved itch and disease control, and data support quarterly or twice-yearly dosing with a favorable safety profile.
The deal also brings APG273, a long-acting combination of zumilokibart and APG333 targeting IL-13 and TSLP for asthma. AbbVie expects EPS dilution of $0.14 in 2026 and about $0.46 in 2027, but reaffirmed 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88.